Marlies L. van Bekkum

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study

Anna van der Voort, Fleur M. Louis, Mette S. van Ramshorst et al. · The Lancet Oncology · 2024 · 43 citations · Full text

Medicine, Oncology, Radiology +14

Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial

Quisette P. Janssen, Jacob L. van Dam, Marlies L. van Bekkum et al. · The Lancet Oncology · 2025 · 31 citations · Full text

Medicine, Oncology, Surgery +13

Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study

Fleur van der Sijde, Marjolein Y.V. Homs, Marlies L. van Bekkum et al. · International Journal of Molecular Sciences · 2021 · 29 citations · Full text

Medicine, Cancer Biology, Oncology +17

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

Nathalie I. Bouwer, Tessa G. Steenbruggen, Joost van Rosmalen et al. · Breast Cancer Research and Treatment · 2021 · 26 citations · Full text

Medicine, Cardiology, Oncology +15

Current palliative chemotherapy trials in the elderly neglect patient-centred outcome measures

Marlies L. van Bekkum, Barbara C. Van Munster, Peter L.M. Thunnissen et al. · Journal of Geriatric Oncology · 2014 · 20 citations

Medicine, Geriatric Medicine, Oncology +14